{"id":6102,"date":"2024-10-03T23:20:16","date_gmt":"2024-10-03T23:20:16","guid":{"rendered":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/?page_id=6102"},"modified":"2026-04-10T19:06:33","modified_gmt":"2026-04-10T19:06:33","slug":"our-funding-sources","status":"publish","type":"page","link":"https:\/\/dnc-test.myddns.me\/cda-foundation\/cdafound.org\/our-funding-sources\/","title":{"rendered":"Our Funding Sources"},"content":{"rendered":"\n

The CDA Foundation receives funding from various sources, including private foundations, commercial organizations, private donors, and government agencies. The majority of the funds come from non-profit organizations. With the exception of the generous support provided by our private donors, the remainder of the funding is generated through participation in a highly competitive proposal process.<\/p>\n\n\n\n

CDA Foundation’s Funding Sources<\/h2>\n\n\n
\n\t\t\t\t
<\/span>
\n

A Comprehensive Breakdown of the CDA Foundation\u2019s Funding Is Presented in the Sankey Chart Below.<\/h2>\n\n\n
\n\t\t\t\t

Our most significant funding source has been the John C. Martin Foundation, which provided support for the establishment of the Polaris Observatory in 2015 and has continued to do so since.  In addition, the Foundation provided funding for elimination demonstration projects in Uzbekistan (elimination of hepatitis B and C viruses (HBV and HCV) in the adult population) and treatment of HBV positive pregnant women in Uganda.  The John C. Martin Foundation has committed to funding the Polaris Observatory until 2030, enabling us to provide pro bono support to countries during that period.<\/p>\n\n\n\n

Our second largest funding source is Gilead Sciences.  The majority of their funding was an $8 million grant (Relink Grants<\/a>) to CDA Foundation.  The funding is used to provide grants to U.S. state departments of health, health centers and universities to find HBV- and HCV-infected individuals who were diagnosed but lost to follow up and link them back to care (Relink<\/a>).  The program is treatment agnostic, and the grantees are free to use any available treatment they deem appropriate. <\/p>\n\n\n\n

Gilead has also provided research grants and grants for HBV\/HCV elimination projects in Uzbekistan, Kazakhstan, and Tajikistan.  Receiving these funds include a highly competitive process where we compete with other organizations.  Gilead Sciences is unique in issuing so many grants to support patients, communities, countries, and to conduct research studies.  CDA Foundation has been successful in securing some of these grants because of our track record. We complete projects on time, within the budget, and achieve what we promise. <\/p>\n\n\n\n

Private individual donors constitute our third-largest source of funding. Our founders are the primary contributors in this category.<\/p>\n\n\n\n

\n
\n
\n
\"\"<\/figure>\n<\/div>\n\n\n\n
\n

Non-Profit Organizations<\/h2>\n<\/div>\n<\/div>\n\n\n\n

The following non-profit organizations have supported the CDA Foundation, listed in order of their contribution. This list is not exhaustive but represents over 90% of all funds received in this category.<\/p>\n\n\n\n